BioSyent Inc., a Canadian specialty healthcare firm, has entered into an agreement to acquire Oral Science Inc., a notable distributor of dental and oral health products headquartered in Brossard, Quebec. The deal, valued at $25.5 million, includes both cash and BioSyent shares, with further payments linked to Oral Science’s performance and sales milestones through 2033. Pending regulatory approvals and other standard conditions, the transaction is expected to close before the end of February 2026.
Founded in 2003, Oral Science has become a key player in Canada’s dental product sector, partnering with advanced dental practices to address periodontal and endodontic diseases, high-risk caries, dry mouth, and oral lesions. The company’s approach integrates diagnosis, monitoring, treatment, home-care solutions, and education. Oral Science derives about one-third of its revenue from proprietary technology and products, while the remainder comes from exclusive distribution deals with international partners. Their sales strategy is split between dental clinics and consumer purchases at retail pharmacies or direct online.
BioSyent’s purchase of Oral Science will diversify its product range and expand its reach among dental professionals, clinics, and consumers. Leadership teams from Oral Science will remain in place, continuing to manage their operations as a standalone business unit within BioSyent Inc. They will also become shareholders of BioSyent through the share consideration. Both companies expect the combined workforce, expertise, and product portfolios to deliver robust growth and enhance value for stakeholders.
This acquisition reflects broader positive trends in the dental equipment and products market. According to recent industry forecasts, the global dental equipment market is projected to grow from approximately $8.31 billion in 2026 to $11.48 billion by 2031. Factors such as increasing awareness of dental health, the need for preventive and cosmetic care, technological advancements, and growing access to dental services are fueling industry expansion. Therapeutic dental equipment, especially products used for treatments, holds the largest share of the market, with hospitals and clinics being primary end users.
BioSyent’s President and CEO, René Goehrum, stated that the acquisition aligns with their goal of profitable growth, portfolio diversification, and long-term value creation. Oral Science’s President, Daniel Ménard, emphasized that the agreement secures a sustainable future for Oral Science and offers new opportunities as part of a public company. Both leaders expressed confidence in their ability to support Canadian dental patients and professionals while growing the combined companies domestically and internationally. BioSyent has structured the deal with a mixture of cash reserves and a short-term loan, maintaining a stable financial position that allows ongoing investment in new product development and market expansion.